WA-TWIN-PROTOCOL
20.6.2024 09:31:27 CEST | Business Wire | Press release
Twin Protocol, a pioneer in the development of ethically engineered, personalized generative artificial intelligence (AI) technology to foster a culture of continuous knowledge sharing, announces a partnership with wellness and tech leaders, Cyberhuman.ai, and Dectec. The three companies are developing cutting-edge solutions that will democratize well-being and guide people around the world on the path of improved health and mindfulness. At the Cannes Creative Festival this week, Dr. Deepak Chopra unveils the first step in this revolutionary approach to sharing well-being knowledge across the globe – his Digital Deepak AI Twin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620183427/en/
Celebrating innovation at Cannes Creative Festival 2024: (pictured from left to right) Bill Inman, CEO of Dectec; Stacey Engle, CEO of Twin Protocol; Deepak Chopra, MD; and Poonacha Machaiah, Co-founder of Cyberhuman.ai., announce the groundbreaking Deepak Chopra AI Twin, a collaboration at the intersection of well-being, AI, and technology. (Photo: Business Wire)
World-renowned pioneer in integrative medicine and personal transformation, Dr. Deepak Chopra previews his digital twin to further his efforts to make chronic disease optional. Digital Deepak is a groundbreaking initiative to integrate advanced technology to more effectively, securely, and personally communicate his timeless wisdom, and guide people along the path of well-being and personal growth.
Interact with Dr. Chopra’s AI Twin here: Digital Deepak. Visitors can ask him questions from a subset of his published books and will even be treated to a sneak peek of his new “Digital Dharma” book, which focuses on the core role of AI in helping individuals achieve well-being and is scheduled for publication in December. Over the coming months, Dr. Chopra’s life’s work will be made available through his digital AI twin.
The partnership between Twin Protocol, Cyberhuman.ai, and Dectec is breaking new ground in the wellness industry. Cyberhuman.ai, an AI platform for personal health and well-being, optimizes lives for peak living at home, work, play, or on the road. The platform uses advanced diagnostics and predictive analytics to provide personalized well-being program recommendations. Dectec is creating the ecosystem and digital wallet that will enable users to make purchases within the ecosystem. Twin Protocol provides the decentralized digital AI twin technology for all healthcare gurus and users, the industry’s most secure, ultra-relatable means of sharing knowledge.
Dr. Chopra’s AI Twin, born out of extensive research and development by Twin Protocol, embodies his vision for guiding individuals on a journey pursuing optimal health and vitality. His AI Twin is poised to revolutionize the future of well-being by offering a holistic approach to wellness that integrates the latest security advancements in AI and blockchain technology. Future updates to the AI Twin will add new communication capabilities and modalities.
Dr. Deepak Chopra shared his perspective on the transformative potential of the AI Twin, stating, “With digital twins and AI technology, it is becoming possible to guide more and more people around the globe on a journey of ever-improving well-being and mindfulness. Over the coming weeks and months, I will share deeper insight through my twin, safely and securely empowering individuals to leverage my assistant as a confidant, health coach, and spiritual guide.”
“The launch of Dr. Deepak Chopra’s AI Twin demonstrates the exceptional vision and capabilities of the Cyberhuman.ai, Dectec, and Twin Protocol team. This is a significant milestone in our journey towards empowering individuals to live their best, most healthy lives,” said Stacey Engle, CEO of Twin Protocol. “By combining cutting-edge technology with his profound wisdom, we are pioneering a new paradigm of well-being that is accessible, personalized, and transformative.”
A unique panel will take place this week at Cannes, exploring the transformative potential of AI and digital twins in enhancing individual well-being.
June 20, 2024
11:00 AM to 12:00 PM
Annex Beach Cannes
Boulevard de la Croisette, Cannes - France
Participants:
- Deepak Chopra – MD
- Poonacha Machaiah – Co-founder, Cyberhuman.ai
- Stacey Engle – CEO, Twin Protocol
- Bill Inman – CEO, Dectec
“AI is reinventing aspects of our world in fundamental ways, including enabling us to create a future where people around the globe can instantly harness the well-being knowledge and insights of global thought leaders such as Dr. Chopra,” said Poonacha Machaiah, co-founder of Cyberhuman.ai. “Through partnerships with world-leading tech innovators like Twin Protocol and Dectec, we are democratizing well-being and helping people live their best lives.”
“When it comes to wellness and health-related information and transactions, its essential that our data is absolutely secure,” said Bill Inman, CEO, Dectec. “With our Web3 platform and collaboration with world-class partners, we’re creating a secure ecosystem that protects users and empowers them to securely manage and improve all aspects of their well-being.”
For more information about Twin Protocol, please visit Twin Protocol.
About Cyberhuman.ai
Cyberhuman.ai is a pioneering advance in personal health and well-being. It is designed as an AI platform to help individuals optimize their lives for peak living across various environments—at home, work, play, or on the road. Leveraging a combination of advanced diagnostics and predictive analytics, the platform offers personalized well-being program recommendations.
About Dectec
Dectec is a pioneering Web3 platform that connects traditional enterprises with advanced AI and blockchain technologies. Specializing in loyalty and rewards programs, Dectec empowers businesses to expand their reach and deepen customer engagement through innovative solutions like user-friendly mobile apps, metaverse experiences, and robotics. The company’s strategy focuses on tapping into new markets with a sophisticated, user-centric wallet system, ensuring clients stay at the forefront of industry innovation for sustained success.
About Twin Protocol
The mission of Twin Protocol’s global venture is to empower individuals and organizations to create secure, dynamic digital versions of themselves to share knowledge, create legacies, and foster continuous learning. Through an advanced AI and blockchain ecosystem, Twin Protocol is revolutionizing the way knowledge and expertise are preserved, shared, and utilized. Twin Protocol, along with strategic partners including SingularityNET, is committed to helping users shape a future where knowledge is an enduring and shared asset. Learn more at Twin Protocol.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620183427/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release
A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom